DK3579874T3 - 1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer - Google Patents

1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer Download PDF

Info

Publication number
DK3579874T3
DK3579874T3 DK18707151.9T DK18707151T DK3579874T3 DK 3579874 T3 DK3579874 T3 DK 3579874T3 DK 18707151 T DK18707151 T DK 18707151T DK 3579874 T3 DK3579874 T3 DK 3579874T3
Authority
DK
Denmark
Prior art keywords
pyrazol
pyrimidin
bromo
amino
cancer treatment
Prior art date
Application number
DK18707151.9T
Other languages
Danish (da)
English (en)
Inventor
Gomez Juan Alberto Camacho
Laria Julio Cesar Castro-Palomino
Sanela Bilic
John Scott Cameron
Danny Roland Howard Jr
Original Assignee
Novartis Ag
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Palobiofarma Sl filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3579874T3 publication Critical patent/DK3579874T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK18707151.9T 2017-02-10 2018-02-08 1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer DK3579874T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762457219P 2017-02-10 2017-02-10
PCT/IB2018/050783 WO2018146612A1 (en) 2017-02-10 2018-02-08 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer

Publications (1)

Publication Number Publication Date
DK3579874T3 true DK3579874T3 (da) 2021-10-11

Family

ID=61274309

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18707151.9T DK3579874T3 (da) 2017-02-10 2018-02-08 1-(4-amino-5-brom-6-(1h-pyrazol-1-yl)pyrimidin-2-yl)-1h-pyrazol-4-ol og anvendelse deraf til behandling af cancer

Country Status (15)

Country Link
US (1) US11078191B2 (enExample)
EP (1) EP3579874B1 (enExample)
JP (1) JP7161481B2 (enExample)
KR (1) KR20190115053A (enExample)
CN (1) CN110290808B (enExample)
AU (2) AU2018217963B2 (enExample)
CA (1) CA3051986A1 (enExample)
DK (1) DK3579874T3 (enExample)
ES (1) ES2893006T3 (enExample)
HU (1) HUE057337T2 (enExample)
IL (1) IL268549B (enExample)
PL (1) PL3579874T3 (enExample)
PT (1) PT3579874T (enExample)
SI (1) SI3579874T1 (enExample)
WO (1) WO2018146612A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106656A1 (en) * 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
JOP20190279A1 (ar) * 2017-05-31 2019-11-28 Novartis Ag الصور البلورية من 5-برومو -2، 6-داي (1h-بيرازول -1-يل) بيريميدين -4- أمين وأملاح جديدة

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
US7119200B2 (en) * 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
WO2008156712A1 (en) 2007-06-18 2008-12-24 N. V. Organon Antibodies to human programmed death receptor pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
TW202442680A (zh) 2008-12-09 2024-11-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011110604A1 (en) 2010-03-11 2011-09-15 Ucb Pharma, S.A. Pd-1 antibody
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
PT2699264T (pt) 2011-04-20 2018-05-23 Medimmune Llc Anticorpos e outras moléculas que ligam b7-h1 e pd-1
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
MX349096B (es) 2011-11-28 2017-07-11 Merck Patent Gmbh Anticuerpos anti-pd-l1 y sus usos.
ES2845609T3 (es) 2013-05-02 2021-07-27 Anaptysbio Inc Anticuerpos dirigidos contra muerte programada-1 (PD-1)
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
BR112015028326A8 (pt) * 2013-06-03 2018-01-23 Novartis Ag combinações de anticorpo anti-pd-l1, inibidor de mek e/ou inibidor de braf, seus kits e seus usos, e composição farmacêutica
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
GB201320729D0 (en) * 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EA201790834A1 (ru) * 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
RS59688B1 (sr) * 2015-08-11 2020-01-31 Novartis Ag 5-bromo-2,6-di-(1h-pirazol-1-il)pirimidin-4-amin za upotrebu pri lečenju raka

Also Published As

Publication number Publication date
RU2019128199A3 (enExample) 2021-05-14
AU2018217963B2 (en) 2020-11-19
HUE057337T2 (hu) 2022-05-28
SI3579874T1 (sl) 2021-11-30
PT3579874T (pt) 2021-10-07
AU2018217963A1 (en) 2019-08-08
IL268549A (en) 2019-09-26
RU2019128199A (ru) 2021-03-10
AU2020256467A1 (en) 2020-11-12
CN110290808A (zh) 2019-09-27
EP3579874A1 (en) 2019-12-18
IL268549B (en) 2021-10-31
KR20190115053A (ko) 2019-10-10
WO2018146612A1 (en) 2018-08-16
US20190359600A1 (en) 2019-11-28
CA3051986A1 (en) 2018-08-16
CN110290808B (zh) 2023-07-11
PL3579874T3 (pl) 2022-02-28
US11078191B2 (en) 2021-08-03
ES2893006T3 (es) 2022-02-07
AU2020256467B2 (en) 2022-03-03
EP3579874B1 (en) 2021-07-21
JP7161481B2 (ja) 2022-10-26
JP2020507569A (ja) 2020-03-12

Similar Documents

Publication Publication Date Title
DK3558997T3 (da) Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3877376T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3331877T3 (da) Pyrazolpyrimidinderivat og anvendelser deraf
DK3280441T3 (da) Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3580211T3 (da) 2-heteroaryl-3-oxo-2,3-dihydropyridazin-4-carboxamider til behandling af cancer
DK3331900T3 (da) Peptider og kombination af peptider til anvendelse ved immunterapi mod prostatacancer og andre cancere
DK3227237T3 (da) Indretning og anvendelse deraf til uv-bearbejdning af fluider
DK3292150T3 (da) Aktiverbare anti-cd166-antistoffer og fremgangsmåder til anvendelse deraf
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3508502T5 (da) Kombination af anti-lag-3-antistoffer og anti-pd-1-antistoffer til behandling af tumorer
DK3319611T3 (da) Oxysteroler og fremgangsmåder til anvendelse deraf
DK3640207T3 (da) Molekularsi scm-15, syntesefremgangsmåde dertil og anvendelse deraf
DK3436022T3 (da) Oxysteroler og fremgangsmåder til anvendelse heraf
DK3345587T3 (da) Beholderholdeelement og medicinsk beholdersæt
DK3380495T3 (da) Peptidforbindelser og peptidkonjugater til behandling af kræft gennem receptor-medieret kemoterapi
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3416957T3 (da) 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes
DK3493812T3 (da) Kombinationer af imetelstat og venetoclax til behandling af akut myeloid leukæmi
DK3692009T3 (da) Biocementationsfremgangsmåde og system
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf